Vector Labs Closes $124M Cash Buyout, Aligning with Acquisition Strategy

Vector Laboratories recently closed a $124 million cash buyout, backed by private equity firm Thompson Street Capital Partners, to accelerate its expansion into protein detection. This new funding enables Vector, a leader in labeling and detection reagents for biomedical research, to embark upon an acquisition strategy while also accelerating the commercialization of labeling and detection technologies for immunohistochemistry, immunofluorescence, glycobiology and bioconjugation.

Through this buyout, Vector Laboratories has gained the flexibility of a well-funded startup combined with a market-tested product portfolio. This will drive research by academic, industrial and clinical researchers around the world.

The buyout was led by Lisa V. Sellers, newly appointed chief executive officer. Prior to taking the helm at Vector Laboratories, Sellers served as chief operating officer at the company. Previously, she served as vice president of marketing at 10x Genomics. In addition, Sellers held leadership roles overseeing the global reagent and instrumentation businesses for Applied Biosystems, Life Technologies and ThermoFisher Scientific.